Important notice: BHI Therapeutic Sciences is a research and education company. Our cellular and exosome products are investigational, are not approved by the U.S. Food and Drug Administration (FDA), and are not intended to diagnose, treat, cure, or prevent any disease. Nothing on this website is medical advice or an offer to sell or a solicitation of an offer to buy any security.
WHAT IS BHI

About us

Welcome to BHI Therapeutic Sciences, Inc., an international biotechnology company dedicated to scientific research and education in the field of stem cells and regenerative medicine. BHI has a team of scientists and medical professionals engaged in the study of stem cells and exosomes. Our research efforts are led by a Scientific Advisory Board composed of scientists and medical professionals active in the field. BHI works with research and clinical partners in various locations. Our cellular products are investigational; they have not been approved or licensed by the FDA, and no statement on this website should be interpreted as a representation that any product is FDA-approved or is the subject of an effective Investigational New Drug (IND) application or Biologics License Application. A cord-blood study is registered at ClinicalTrials.gov (Identifier: NCT03735277). Our work is focused on advancing regenerative medicine research responsibly and in accordance with applicable regulations.

innovate
Innovative
BHI Therapeutic Sciences is engaged in biotechnology research, studying stem cells and exosomes in the field of regenerative medicine.
biotech
Biotechnology
BHI Therapeutic Sciences is a biotechnology company active in the field of stem cell and regenerative medicine research.
advanced
Stem cell research
BHI Therapeutic Sciences studies stem cells and exosomes as part of ongoing regenerative medicine research. Our products are investigational and are not FDA-approved.
intro
Why choose our stock

BHI Therapeutic Sciences is the US entity of the Blue Horizon International family of companies and is engaged in stem cell and regenerative medicine research. Our Scientific Advisory Board supports research in the field, and our work is grounded in published, peer-reviewed scientific literature. Our cellular products are investigational, are not FDA-approved, and are not intended to diagnose, treat, cure, or prevent any disease. A cord-blood study is registered at ClinicalTrials.gov (Identifier: NCT03735277). Any decision to invest should be based solely on the official offering materials and made in consultation with your own advisors.

Biotechnology research

BHI Therapeutic Sciences is engaged in stem cell and regenerative medicine research. Our cellular products are investigational and are not FDA-approved.

Scientific Advisory Board

BHI Therapeutic Sciences has assembled a Scientific Advisory Board of scientists and medical professionals who support its research and education activities.

International research network

BHI Therapeutic Sciences works with research and clinical partners across multiple geographic locations.

Security & control over money

Provide high levels of security allowing the user to keep control money.
PROBLEM & SOLUTION

The Problem & Our Solution

Problem
Regenerative medicine is an emerging and evolving field of scientific study. BHI Therapeutic Sciences works to advance recognition of stem cell research through peer-reviewed publication and collaboration with the scientific community.
Solution
BHI Therapeutic Sciences focuses on publishing and presenting its research at scientific conferences and in peer-reviewed journals. Cellular material used in its research studies is collected consistent with Good Tissue Practice, and studies are conducted following review by an Institutional Review Board and in accordance with Good Clinical Practice. BHI's cellular products are investigational and have not been approved by the FDA.
circles
pattern-layer
Allocation & Funds Distribution
Invest now
  • Funding Allocation
funds
Core BHI Therapeutic Sciences Staff Expenses: 14.77%
Setup Costs For All the Clinics: 206.34%
Misc Expenses: 29.55%
Ongoing Stem Cell Project Costs: 20.14%
Taxes: 2.3%
Emergency Funds: 27.02%
graph
circles

Start time

15 March 2023

Company

BHI

PRICE PER SHARE

$1.00

PRE VALUATION

120 M

AMOUNT RAISED

1.2 M

DEADLINE

Ongoing
OFFERING TYPE
COMMON
$1/share
MAX SUPPLY
12.0 M
$1/share
MIN INVESTMENT
$100 US Domestic
€100 International
$1/share
MAX INVESTMENT
$1,000,000.00
$1/share
SHARES OFFERED
Class B
$1/share
Road map

Our Strategy & Project Plan

Stage 1
FDA
Expanded Access Compassionate Care IND applications filed
Stage 2
FDA
Interact and Pre-IND Meetings to qualify for Fast Track Designation
Stage 3
FDA
Initial IND filed
Stage 4
FDA
Phase 1/2 Open Label trial begin
Stage 5
FDA
Phase 3 Randomized, Double-Blind, Placebo trial begins
Stage 6
FDA
BLA Review begin
Stage 7
Benefits
FDA BLA Approval granted
Buisness plan

Overview

BHI Therapeutic Sciences is a healthcare consulting company that combines research, education, and philanthropy in the field of regenerative medicine. Its research activities focus on the scientific study of stem cells and exosomes. The BHITS team is engaged in multiple stem cell research projects and has published several peer-reviewed research papers. Its research has involved collaboration with partners in various locations, including the U.S., Jamaica, and Slovakia. BHITS's cellular products are investigational; they have not been approved or licensed by the FDA, and nothing on this page should be interpreted as a claim that any product is FDA-approved or is safe or effective for the treatment of any disease or condition.
Business Plan
funds
circles
circle
OUR TEAM

The Leadership Team

founder
Dr. Brian Mehling
Founder, CMO
doreen
Doreen Santora
CEO
katarina
Katarina Novakova
President, BHI Slovakia
klara
Klara Doert
President of international development
leandro
Leandro Silva
President, BHI Performance

Scientific Advisory Board

wu
Dongcheng Wu
Chief science officer Ph.D., Wuhan University, Wuhan, China
mike
Michael Platt
Ph.D., Biological Anthropology, University of Pennsylvania
vicky
Vicky Yamamoto
Ph.D. Chair of the SAB at BHI, Chair of the Board of Directors
FAQs

Frequently Questions

  • General
  • Equity Offering
  • Legal
What is Blue Horizon's focus and mission?
Blue Horizon's focus is on regenerative medicine, and its mission is to advance scientific research and education in the field of stem cells and exosomes.
What kind of stem cells does Blue Horizon study?
BHI Therapeutic Sciences studies cells derived from placental cord material collected at C-section with no injury to the baby or the mother. BHI Therapeutic Sciences never uses cells harvested from embryonic or fetal tissue. Its cellular products are investigational and are not FDA-approved.
How does Blue Horizon's research and development process work?
Blue Horizon conducts research in the field of stem cells and regenerative medicine, working with experts in the field. Its research studies are conducted under Institutional Review Board oversight in accordance with Good Clinical Practice.
BHI Therapeutic Sciences has published peer-reviewed research in the field of stem cell science.
What are Blue Horizon's growth prospects?
Blue Horizon's research activities and partnerships position the company to participate in the growing regenerative medicine research field. This is a forward-looking statement and not a guarantee of any outcome.
What is Blue Horizon's financial performance?
Financial information is provided solely through the company's official offering materials. Prospective investors should review those materials and consult their own financial and legal advisors before making any investment decision.
What are the terms and conditions of the investment, such as the length of the investment and any potential risks involved?
The investment is in the form of equity, meaning the term is infinite and it is not a loan or convertible note. The risk involved is the complete loss of the investment.
What is the minimum investment amount?
The minimum investment amount is $1.
What are the potential returns for investors?
The potential returns for investors are not specified, but investors can expect an increase in valuation.
Is there any accreditation requirement for investors?
There is no accreditation requirement for investors.
Is there a cap on the investment amount?
There is no cap on the investment amount, but if an investor wants to invest millions, they will be evaluated for accredited investor status.
Are there any restrictions on who can invest, such as certain countries or regions?
There are no restrictions on who can invest, but the company is based in the USA.
We will soon be offering a crowdfunding opportunity in our sister company Blue Horizon International, which is a Luxenberg-based international company with plans to open in dozens of countries in the coming 12 to 24 months and already to open and functioning clinics.
Is there an exit strategy for investors?
The company plans to go public, and investors will be able to sell their shares on a public exchange.
Are legal or financial professionals involved in the investment process?
Yes, legal and financial professionals are involved in the investment process. (The FDA does not register or endorse securities offerings; any securities matters are handled under applicable U.S. securities laws.)
Are there any legal or regulatory requirements that the investment page needs to comply with?
The investment opportunity is registered with the US SEC.
Is there any rewards system for investors?
There will be an award system offered to investors based on the dollar amount invested
What are the securities laws that Blue Horizon must comply with during the seed round of funding?
Blue Horizon must comply with federal and state securities laws, including the Securities Act of 1933 and the Securities Exchange Act of 1934. It's best to consult with a lawyer for more information.
What type of documentation will be required for an investor to participate in the seed round of funding for Blue Horizon?
An investor will likely be required to complete documentation such as a subscription agreement and investor questionnaire. It's best to consult with a lawyer or the company for more information.
What are the rights and responsibilities of the investors in Blue Horizon during the seed round?
The rights and responsibilities of the investors in Blue Horizon during the seed round will depend on the terms of the investment and the type of equity offered. It's best to consult with a lawyer or the company for more information.
What is the process for the investor to exit their investment in Blue Horizon
The process for an investor to exit their investment in Blue Horizon will depend on the terms of the investment and the type of equity offered. It may include options such as a secondary market sale or a buyback by the company. It's best to consult with a lawyer or the company for more information.
Portfolio

Our Porfolio

Explore Our Portfolio
ALPHA BLU Skincare
Alpha Blu Skincare offers a range of cosmetic skin care products formulated with a proprietary ingredient, BlueCellule-CM™. The product line is designed to improve the look and feel of skin, including the appearance of fine lines, wrinkles, and skin texture. These are cosmetic products and are not intended to diagnose, treat, cure, or prevent any disease.
Learn More
Rejuve
BHI Rejuve, led by Dr. Brian Mehling, focuses on anti-aging science and wellness. Services offered by licensed clinicians include hormone optimization programs, supplement protocols, and related wellness services. Any medical services are provided by licensed practitioners; information here is general and is not medical advice.
Learn More
BHI performance
Description of Product 1. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Learn More